مواقع التدريسيينجامعة الكوفة
دنيا حبيب شنين العرداوي
أستاذ مساعد

دنيا حبيب شنين العرداوي

English Version
0بحث منشور
0محاضرة
0خبر

الملف الشخصي

تخرّجتُ من كلية الصيدلة – جامعة الكوفة للعام الدراسي 2014–2015، حيث حصلتُ على المرتبة الأولى على الدفعة والأولى على مستوى العراق. تم تعييني لاحقًا على الملاك التدريسي لكلية الصيدلة – جامعة الكوفة تقديرًا لإنجازي الأكاديمي.
وفي عامٍ لاحق، قُبلتُ في دراسة البورد في اختصاص الصيدلة السريرية في مدينة الطب – بغداد، واستمرت مدة الدراسة أربع سنوات.
تخرّجتُ بتاريخ 13/12/2022 متصدّرةً زملائي بالمرتبة الأولى على الدفعة.

البحوث المنشورة

4
2025

Impact of Cisplatin on the Incidence of Nephrotoxicity in Patients at the National Oncology Teaching Hospital in Al-Najaf Province, Iraq

الباحثونDunya Habeeb Shnain، Aseel Hadi Abdulameer
المجلةSurgery, Gastroenterology and Oncology
التاريخ2025-05-02
مختصر البحث

Background: nephrotoxicity is one of the significant complications of cisplatin. Aim of study: to evaluate the impact of cisplatin on nephrotoxicity in patients at the National Oncology Teaching Hospital in Al-Najaf Province. Patients and methods: An observational, cohort study was conducted by 40 patients at the National Hospital for Oncology and Hematology in Al-Najaf Al-Ashraf, Iraq. Results: The study shows significant differences in urea and creatinine levels before and after cisplatin treatment with p-values of 0.381, 0.036, respectively. Cisplatin treatment significantly increased urea and creatinine levels in both genders, with females experiencing a more pronounced decrease after four months than men. Conclusion: Our findings indicate a high incidence of nephrotoxicity in Cisplatin patients, with males at greater risk than females. This is influenced by Urea and Creatinine levels before, 2 months after, and 4 months after Cisplatin treatment. Keywords: cisplatin, nephrotoxicity, serum creatinine level, BUN levels

2025

Evaluating the Current Practice in The Preventing of Venous Thromboembolism in Hospitalised Patients with Cancer in Najaf Province, Iraq

الباحثونDunya Habeeb Shnain، Ibtehal Mohammed Khudhair, Karam Khudhair Abbas, Rawaa Shareef, Sara Omar Ahmed
المجلةEurasian Journal of Oncology
التاريخ2025-05-30
مختصر البحث

Introduction. Cancer is linked to a hypercoagulable state, resulting in a four-fold increase in the risk of thrombosis, along with an elevated risk of bleeding. Patients with cancer who receive chemotherapy, thromboembolism is considered the second leading cause of mortality. Malignancy is linked to a higher risk for both thromboembolic and hemorrhagic problems. Purpose. To assess the present practice in the prevention of venous thromboembolism in hospitalized cancer patients. Materials and methods. A cross-sectional study, it involved 70 patients and was conducted at the National Teaching Hospital for Oncology in Najaf Governorate, and the monitoring was conducted during the period from September 15 to February 15 and this study revealed that the type of anticoagulant that administered for hospitalize patient with cancer is enoxaparin according to Padua score. Results. The study included 70 participants, predominantly aged 57–70 years (48.6%), with a greater number of females (57.1%) than males (42.9%). Most participants had a weight exceeding 70 kg (67.1%). Conclusion. The study reveals that Enoxaparin is the preferred anticoagulant for hospitalized cancer patients, as it is effective and prevents bleeding, making it the preferred treatment due to the risk of thrombosis. Keywords: cancer, venous thromboembolism, chemotherapy, anticoagulant

2025

Evaluating the current practice in the preventing of nausea and vomiting in hospitalized patients with cancer in Najaf province

الباحثونDunya Habeeb Shnain، Ahmed Emad Mohammed, Rawaa H. Shareef
المجلةKufa Journal of Pharmaceutical Sciences
التاريخ2025-03-30
مختصر البحث

Cancer is a group of diseases that cause by genetic or epigenetic alterations in the somatic cells and characterized by uncontrolled cellular growth which may be spread to other organ. Chemotherapy, surgery and radiotherapy that use in treatment of cancer are known risk factors for Nausea and vomiting and higher incidence in patient received chemotherapy and evidence indicates that the absolute danger depends on emetogenicity of chemotherapy, so highly emetogenic drugs have higher incidence for nausea and vomiting .Many types of antiemetic agents with different mechanisms of action have been developed for chemotherapy induce nausea and vomiting. The most commonly used antiemetic agents are 5-HT3 antagonists, corticosteroids, and NK1 receptor antagonists and the aim of this study to evaluate the current practice in the preventing of nausea and vomiting in hospitalized patients with cancer and this study is a cross-sectional study, it involved 100 patients and conducted at National Teaching Hospital for Oncology in Najaf province. The monitoring was conducted during the period from September 15 to November 15 and this study included 100 participants, including male gender (45%) and female gender (55%) with variation in age 24-34y ) % 5 ( ) % ,35-45y (12%), 46-56y (38%), 57-67y(37%) ,68-80y (8%),The duration of antiemetic for 2days (8%) and for 3days 92 ( nausea ,vomiting and diarrhea ) , % and many causes of admission such as for receive chemotherapy (26%), 14 ( . Keywords: Cancer, Chemotherapy, Nausea and vomiting, Antiemetics

2024

Frequency of dyspnea related to intake of ticagrelor or clopidogrel in patients with chronic coronary syndrome undergoing coronary intervention

الباحثونDunya Habeeb Shnain، Ghassan Mohammed Mahmood, Sara Omar Ahmed
المجلةCardiovascular therapy and prevention
التاريخ2024-04-29
مختصر البحث

In patients with chronic coronary syndrome, ticagrelor decreases car diovascular events more efficiently than clopidogrel. In several studies investigating novel P2Y12 inhibitors dyspnea has been detected. A rise of adenosine blood levels is supposed to be one of cases of dyspnea induced by ticagrelor. Dyspnea is a prevalent and complex symptom. It is associated with deterioration of the quality of life and hospital readmission. Aim. To determine the frequency of dyspnea related with ticagrelor or clopidogrel intake in patients with stable coronary artery disease undergoing coronary intervention. Also, to determine which patients could continue ticagrelor intake and which patients couldn’t, and show the causes of ticagrelor discontinuation. Material and methods. Between October 2023 and January 2024, an observational prospective comparative case-control study was conducted at Baghdad Heart Center in Baghdad Teaching Hospital in Medical City. In this study, individuals with stable coronary artery disease who just had therapeutic catheterization and dual antiplatelet therapy were included. The patients from group 1 received aspirin and ticagrelor, while those from group 2 received aspirin and clopidogrel. Results. A total of 120 patients were included. With the ticagrelor intake, the severity of dyspnea was classified as mild 64.2% (77 [120]) and moderate 19.1% (23 [120]). About 16.7% (20 [120]) had no dyspnea at all. The difference between patients who continued ticagrelor intake (16%) and those who stopped using it (84%) was significant. With clopidogrel intake no dyspnea was recorded. Conclusions. According to our findings, the risk or occurrence of dys pnea is only evident in patients who received ticagrelor. When com pared to irreversible P2Y12 inhibitors like clopidogrel, the reversible P2Y12 antagonist ticagrelor has a higher incidence of dyspnea in increasing order. Keywords: dyspnea, ticagrelor, clopidogrel, chronic coronary syn drome, coronary intervention.

المحاضرات

5

الأخبار والإعلانات

4
الأخبار 2025-11-06

ندوة علمية تحت عنوان :من البحث العلمي إلى الواقع العملي: آليات تحويل المعرفة العلمية إلى ممارسة صيدلانية سريرية فعّالة

اقام فرع الصيدلة السريرية ندوة علمية حول ( آليات تحويل المعرفة العلمية إلى ممارسة صيدلانية سريرية فعّالة) حيث تهدف هذه الندوة العلمية إلى تسليط الضوء على أهمية تحويل نتائج البحوث العلمية إلى ممارسات عملية تسهم في تحسين جودة الرعاية الصيدلانية والنتائج العلاجية للمرضى. تتناول الندوة آليات تطبيق الأدلة البحثية في الممارسة السريرية، ودور الصيدلي السريري في تحليل الدراسات وتوظيفها في اتخاذ القرار العلاجي المبني على الدليل العلمي

الأخبار 2025-11-04

حملة توعوية حول الكشف المبكر عن سرطان الثدي

اقام فرع الصيدلة السريرية حملة توعوية بمناسبة شهر الذي اعدته منظمة الصحة العالمية شهر التوعية بسرطان الثدي وقد شارك في هذة الحملة طلاب كلية الصيدلة حيث نشروا البوسترات الدالة على هدف الحملة الاسمى وزينوا جدارية العرض في الكلية باللون الوردي كناية عن التمسك بالوقاية خير من العلاج

الأخبار 2025-11-04

نشاط طلابي علمي للتوعية حول مرض السكري

نظم مجموعة من تدريسي كليتنا مع وحدة الانشطة الطلابية نشاط طلابي علمي للتوعية حول مرض السكري ( الاعراض , التشخيص وطرق العلاج ) مع مجموعة من طلاب المرحلة الخامسة

الأخبار 2025-11-04

دورة حول الدور الفعال لدواء روكسوليتينيب في علاج مرض البهاق: إنجاز كبير في مجال الأمراض الجلدية

اقام مجموعة من تدريسي كلية الصيدلة دورة حول مرض البهاق وماهي الادوية المستخدمة في علاج هذا المرض وماهو دور ruxolitinib في علاج هذا المرض

عرض التفاصيل